Publication

End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO.

Journal Paper/Review - Jan 31, 2023

Units
PubMed
Doi
Contact

Citation
Di Cosimo S, Ciniselli C, Pizzamiglio S, Cappelletti V, Silvestri M, El-Abed S, Izquierdo M, Bajji M, Nuciforo P, Huober J, Cameron D, Chia S, Gomez H, Iorio M, Vingiani A, Pruneri G, Verderio P. End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO. Front Oncol 2023; 12:1028825.
Type
Journal Paper/Review (English)
Journal
Front Oncol 2023; 12
Publication Date
Jan 31, 2023
Issn Print
2234-943X
Pages
1028825
Brief description/objective

The absence of breast cancer cells in surgical specimens, , pathological complete response (pCR), is widely recognized as a favorable prognostic factor after neoadjuvant therapy. In contrast, the presence of disease at surgery characterizes a prognostically heterogeneous group of patients. Here, we challenged circulating microRNAs (miRNAs) at the end of neoadjuvant therapy as potential prognostic biomarkers in the NeoALTTO study.